Two Hands Corporation Begins External Beta Testing for EntangleX Quantum Simulator

Two Hands Corporation (OTC: TWOH), changing its name to Quantum X Inc., said it has begun external beta testing for EntangleX, a browser-based, GPU-accelerated classical quantum circuit simulator. The beta will be run with selected partners to assess usability, workflow, results display, and stability, with cloud and on-prem options. Further enhancements are planned later in 2026.

Original reporting
Published Aug 1, 2026, 12:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 1, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Two Hands Corporation Begins External Beta Testing for EntangleX Quantum Simulator — source image
Decision brief

The 30-second read

$TWOHNeutralLow
01

Why it matters

The announcement is a product development milestone that could improve credibility with partners, but it does not provide financial metrics or adoption proof.

02

Market read

Traders may view this as incremental progress toward a software release, but the lack of commercial terms limits immediate trading impact.

03

What to watch

Beta success criteria (usability, stability) are qualitative, and the OTC micro-cap’s liquidity and execution risk could dominate any sentiment effect.

Relevance 4/10Novelty 5/10Timing: external beta phase begins now, with enhancements expected later in 2026

Background

Two Hands Corporation is reportedly changing its corporate identity to Quantum X Inc. and has been developing EntangleX internally.

Company-level read

Ticker impact

$TWOHNeutralMedium confidence
Context

Two Hands Corporation says EntangleX’s base UI is open to selected external partners for third-party beta testing, signaling product progress.

Expected impact

Near-term impact likely limited unless beta feedback leads to measurable adoption or a dated commercial release.

Evidence & confidence

The article discloses a new phase (external beta) and feature scope, but provides no revenue, pricing, or signed customer commitments.

Market effects

Adds incremental signal for classical quantum simulation tooling, but no clear read-through to public peers is provided.

None indicated.

None indicated.

Counterpoint

Because EntangleX is classical simulation and the article gives no commercial release date or contracts, the beta may not translate into near-term monetization.

Key entities

  • Two Hands Corporation

    OTC-listed firm developing EntangleX and initiating external beta testing.

  • EntangleX

    Browser-based, GPU-accelerated classical quantum circuit simulation software.

  • Ujjwal Roy

    Project lead cited for internal development of EntangleX.

  • Emil Assentato

    CEO cited for the external beta announcement.

Related articles

$NVDAMedAI 8/10

NVIDIA To Expand Global Manufacturing Capacity To Meet AI Demand

NVIDIA (NVDA) is partnering with six firms to expand global manufacturing capacity for AI infrastructure. Projects include substrate, packaging, testing, and optical engine expansions, with new facilities expected to come online between 2027 and 2028. NVIDIA's stock was up 1.87% in pre-market trading.

$KYTXMedAI 8/10

Kyverna reports one-year data for SPS therapy miv-cel

Kyverna Therapeutics (KYTX) reported one-year data from its KYSA-8 trial of miv-cel, a CAR T-cell therapy for stiff person syndrome. 77% of patients showed at least 20% improvement in mobility, and 67% of patients no longer needed walking aids. The trial met all secondary endpoints, with no high-grade cytokine release syndrome or neurotoxicity reported.

$MRNAHighAI 8/10

Moderna Stock Is Up 600% This Year — But the Real Story Is What It’s Building Next

Moderna's stock has surged 600% in 2023, reaching near 52-week highs, driven by positive Phase 3 results for its personalized cancer vaccine in partnership with Merck. The company's market cap is now $96 billion, but analysts are divided, with average price targets around $123. Moderna's revenue has declined to $1.94 billion, with a net loss of $2.82 billion. The success of its oncology bets remains uncertain.